<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03173183</url>
  </required_header>
  <id_info>
    <org_study_id>2060302-1401-03</org_study_id>
    <nct_id>NCT03173183</nct_id>
  </id_info>
  <brief_title>Treatment of Functional Dyspepsia With Genuine Regional Rhizoma Atractylodis</brief_title>
  <official_title>Clinical Research on Treatment of Functional Dyspepsia With Genuine Regional Rhizoma Atractylodis: a Randomized Double-blind Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China Academy of Chinese Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized double-blind placebo controlled trial aim to compare the efficiency of
      genuine regional and non-genuine regional Rhizoma Atractylodis in treating functional
      dyspepsia. This study will also observe the clinical safety of genuine regional Rhizoma
      Atractylodis.The trial will be conducted in Xiyuan Hospital of China Academy of Chinese
      Medicine Sciences and Dongzhimen Hospital of Beijing University of Chinese Medicine.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2017</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The research is designed by randomized, double-blind, placebo and parallel clinical control.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disappearance rate of dyspepsia</measure>
    <time_frame>Eight weeks</time_frame>
    <description>The evaluation is divided into five levels: symptoms disappeared; significant improved; moderate improved, no change; deteriorated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Short-Form Leeds Dyspepsia Questionnaire, SF-LDQ</measure>
    <time_frame>Eight weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nepean Dyspepsia Index, NDI</measure>
    <time_frame>Eight weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Efficiency of Genuine Regional and Non-genuine Regional Rhizoma Atractylodis in Treating FD</condition>
  <arm_group>
    <arm_group_label>genuine regional Rhizoma Atractylodis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Granules of genuine regional Rhizoma Atractylodis:
Maozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd., orally administration, 9g per time, 3 times a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-genuine regional Rhizoma Atractylodis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Granules of non-genuine regional Rhizoma Atractylodis (Luotian, Hubei province) :
Luozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd., orally administration, 9g per time, 3 times a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo granules: Simulants (granule), 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Group Co., Ltd., orally administration, 9g per time, 3 times a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>genuine regional Rhizoma Atractylodis (Maozhu granule)</intervention_name>
    <description>Maozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd.
Luozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd.
Simulants (granule), 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Group Co., Ltd.</description>
    <arm_group_label>genuine regional Rhizoma Atractylodis</arm_group_label>
    <arm_group_label>non-genuine regional Rhizoma Atractylodis</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
    <other_name>non-genuine regional Rhizoma Atractylodis (Luozhu granule)</other_name>
    <other_name>placebo granules</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Meeting the FD Rome â…¢ diagnosis standard;

          2. Meeting TCM differentiated diagnosis standard of the spleen deficiency with dampness
             pattern;

          3. Without taking any medicines affecting gastric motility in the recent 14 days;

          4. Between 18 and 65 years old;

          5. Voluntary participation in the trial and signing informed consent.

        Exclusion Criteria:

          1. Combined irritable bowel syndromes; combined peptic ulcer, erosive gastritis, atrophic
             gastritis, abdominal surgery history, gastric mucosa with severe dysplasia or
             pathological diagnosis of suspected malignant transformation; combined
             gastroesophageal reflux disease, irritable bowel syndrome with overlapping syndromes.

          2. Patient whose differentiation is not clear or who doesn't belong to the spleen
             deficiency with dampness pattern.

          3. Women in pregnancy, breastfeeding or have fertility plans recently; the legally
             disabled (blind, deaf, dumb, mental retardation, mental disorders, physical
             disability)

          4. Patients with endocrine and metabolic diseases such as connective tissue diseases,
             diabetes, menopausal syndromes; patients combined with heart rate disorder, severe
             diseases in cardiovascular, brain, liver, lung, kidney and hematopoietic systems,
             acute and chronic infectious diseases, malignant tumors, mental illness.

          5. Allergy to the trial drug.

          6. With suspected or definite alcohol, drug abuse history.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanming Xie, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>China Academy of Chinese Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yin Zhang, M.D.</last_name>
    <phone>8617710830835</phone>
    <email>coolzhangyin@sina.com</email>
  </overall_contact>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2017</study_first_submitted>
  <study_first_submitted_qc>May 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2017</study_first_posted>
  <last_update_submitted>May 30, 2017</last_update_submitted>
  <last_update_submitted_qc>May 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>China Academy of Chinese Medical Sciences</investigator_affiliation>
    <investigator_full_name>Yanming Xie</investigator_full_name>
    <investigator_title>Executive director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

